Across TCGA pan-cancer cohorts, PABPC1L2B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PABPC1L2B data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PABPC1L2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PABPC1L2B expression acts as an unfavorable survival marker.

LIHC are the cancer types where PABPC1L2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.198	0.777	.006	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: PABPC1L2B tumor-vs-normal RNA expression · all PABPC1L2B data types